Terns Pharmaceuticals, Inc. is making significant strides in the biopharmaceutical landscape with the announcement of a substantial funding round that raised $225 million. This clinical-stage company is dedicated to developing a diverse portfolio of small-molecule product candidates aimed at tackling serious health challenges, particularly in the fields of oncology and obesity. Terns’ innovative pipeline features three key clinical-stage development programs, including a next-generation allosteric BCR-ABL inhibitor and a small-molecule GLP-1 receptor agonist, alongside a THR-β agonist and preclinical GIPR modulator programs. The funds acquired in this latest round will be instrumental in advancing these critical projects, allowing Terns to continue its commitment to delivering groundbreaking therapies that can significantly improve patient outcomes. As the company prepares to push forward with clinical trials and expand its research capabilities, Terns Pharmaceuticals stands poised to make a substantial impact in treating some of the most pressing health concerns facing today’s society. This funding round not only reflects investor confidence in Terns’ innovative approach and the potential of its product candidates but also positions the company strategically for future growth and success in the competitive biopharmaceutical market. For updates on Terns’ progress and additional information on its promising pipeline, please visit their website at www.ternspharma.com.
Centessa Pharmaceuticals Secures $225 Million Funding Round to Propel Terns Pharmaceuticals' Biopharmaceutical Innovations!
Recently funded · $225.0MBiopharmaceutical
Get the full Centessa Pharmaceuticals company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
